Investment bank issues rating upgrades for UCB, while an analyst firm raises the outlook on the company's stock.
6 reports, 2 independent
Updated Sat 00:00
Mostly repetition
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Investment bank issues rating upgrades for UCB, while an analyst firm raises the outlook on the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UCB
biopharmaceutical company headquartered in Brussels, Belgium
-
Keefe, Bruyette & Woods
investment bank
Related events
- Keefe, Bruyette & Woods issued research reports and analysts boosted the price target for Capital Bancorp stock.
- Keefe, Bruyette & Woods raised its price objective for Washington Trust Bancorp, Inc. on October 21, 2026.
- CIBC restated a rating on Royal Bank of Canada shares, and Keefe, Bruyette & Woods initiated coverage on the stock.
- Financial firms Keefe, Bruyette & Woods and TD Cowen issued rating and price target updates, alongside company disclosures filed with the SEC.
- Analysts increased price objective for WSFS Bank.